Abstract
We report a case in which multidisciplinary treatment was effective for hepatocellular carcinoma (HCC) with cranial and skeletal muscle metastases. A 55-year-old male with HCC received sorafenib for lung metastases. He was admitted to our hospital due to the skull metastasis detected by fluorodeoxyglucose positron emission tomography (FDG-PET). The patient underwent resection for skull metastasis. After the surgical treatment, he was treated with sorafenib again. Eight months after craniectomy, FDG-PET showed FDG uptake in the semimembranosus and semitendinosus muscles. Histopathological examination of the muscle biopsy revealed HCC muscle metastasis. Sorafenib treatment was discontinued. The investigational new drug (tegafur-gimeracil-oteracil) and tegafur-uracil were used for the treatment. These treatments proved to be ineffective as the lung metastases enlarged and new metastases appeared on the mediastinal lymph nodes and dura cava. The patient was unable to walk due to the enlarged thigh muscle metastases. Sorafenib was re-administered, which reduced the enlargement of the lung and mediastinal lymph nodes. Dural metastases were treated with resection and radiotherapy. Additional radiation therapy to the thigh muscles relieved the patient from pain experienced during walking. Sorafenib treatment was continued for the next 3 years. The patient survived for 4 years after the skull resection.
References
Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–62.
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.
Bhatia R, Ravulapati S, Befeler A, et al. Hepatocellular carcinoma with bone metastases: incidence, prognostic significance, and management-single-center experience. J Gastrointest Cancer. 2017;48:321–5.
D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–31.
Hiraoka A, Michitaka K, Kumada T, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer. 2017;6:325–36.
Fukutomi M, Yokota M, Chuman H, et al. Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2001;13:1083–8.
McIver JI, Scheithauer BW, Rydberg CH, et al. Metastatic hepatocellular carcinoma presenting as epidural hematoma: case report. Neurosurgery. 2001;49:447–9.
Goto T, Dohmen T, Miura K, et al. Skull metastasis from hepatocellular carcinoma with chronic hepatitis B. World J Gastrointest Oncol. 2010;2:165–8.
Hsieh CT, Sun JM, Tsai WC, et al. Skull metastasis from hepatocellular carcinoma. Acta Neurochir (Wien). 2007;149:185–90.
Kim YS, Moon KS, Lee KH, et al. Spontaneous acute epidural hematoma developed due to skull metastasis of hepatocelluar carcinoma: a case report and review of the literature. Oncol Lett. 2016;11:741–4.
Chye CL, Lin KH, Ou CH, et al. Acute spontaneous subdural hematoma caused by skull metastasis of hepatocellular carcinoma: case report. BMC Surg. 2015;15:60.
Sadik KW, Dayoub H, Bonatti H. Superior sagittal sinus tumor eroding through the skull: an unfamiliar presentation of hepatocellular carcinoma and literature review. Case Rep Surg. 2019;2019:5945726.
Chamoun RB, DeMonte F. Management of skull base metastases. Neurosurg Clin N Am. 2011;22(61–6):vi–ii.
Stark AM, Eichmann T, Mehdorn HM. Skull metastases: clinical features, differential diagnosis, and review of the literature. Surg Neurol. 2003;60:219–25 (discussion 25-6).
Soffietti R, Cornu P, Delattre JY, et al. EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol. 2006;13:674–81.
Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA. 1998;280:1485–9.
Wu MH, Wu YM, Lee PH. The psoas muscle as an unusual site for metastasis of hepatocellular carcinoma: report of a case. Surg Today. 2006;36:280–2.
Yau T, Wong H, Chan P, et al. Intramuscular recurrence in a hepatocellular carcinoma patient with indolent disease course. World J Surg Oncol. 2008;6:42.
Sano T, Izuishi K, Takebayashi R, et al. Education and imaging hepatobiliary and pancreatic: isolated diaphragmatic metastasis from hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:1475.
Sirigu D, Loi L, Mura R, et al. Muscle metastasis from hepatocellular carcinoma in a patient treated with TACE. J Ultrasound. 2009;12:45–7.
Michalaki V, Zygogianni A, Kouloulias V, et al. Muscle metastasis from hepatocellular carcinoma. J Cancer Res Ther. 2011;7:81–3.
Furumoto K, Miura K, Nagashima D, et al. Solitary metastasis to the intercostal muscle from hepatocellular carcinoma: a case report. Int J Surg Case Rep. 2012;3:322–6.
Jiang H, Wang Z, Xian J, et al. Bilateral multiple extraocular muscle metastasis from hepatocellular carcinoma. Acta Radiol Short Rep. 2012;1:1–3.
Jo S, Shim HK. A patient who has survived for a long period with repeated radiotherapies for multifocal extrahepatic metastases from hepatocellular carcinoma. Radiat Oncol J. 2013;31:267–72.
Subramaniam N, Hiremath B, Pujar A. Metastasis of diffuse hepatocellular carcinoma to an extremely unusual site. BMJ Case Rep. 2013;2013:bcr2013200437.
Traficante D, Assalone P, Tomei F, et al. A case report of HCC cutaneous metastasis. J Gastrointest Oncol. 2014;5:E65–7.
Rahim EA, Noh MS, Ngah NA, et al. Hepatocellular carcinoma with disseminated skeletal muscle metastasis. Acta Radiol Open. 2017;6:2058460117716705.
Takahashi K, Putchakayala KG, Safwan M, et al. Extrahepatic metastasis of hepatocellular carcinoma to the paravertebral muscle: a case report. World J Hepatol. 2017;9:973–8.
Orita K, Sakamoto A, Okamoto T, et al. Solitary muscle metastasis of hepatocellular carcinoma to the biceps femoris muscle with only elevated serum PIVKA-II: a case report. Am J Case Rep. 2019;20:306–9.
Nakayama A, Arai J, Otoyama Y, et al. Muscular metastasis of hepatocellular carcinoma: case report and literature review. Intern Med (Tokyo, Japan). 2021. https://doi.org/10.2169/internalmedicine.7200-21.
Song Q, Sun XF, Wu XL, et al. Skeletal muscle metastases of hepatocellular carcinoma: a case report and literature review. World J Clin Cases. 2021;9:3334–41.
Cha J, Seong J, Lee IJ, et al. Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. Yonsei Med J. 2013;54:1178–85.
Guo X, Xu Y, Wang X, et al. Advanced hepatocellular carcinoma with bone metastases: prevalence, associated factors, and survival estimation. Med Sci Monit. 2019;25:1105–12.
Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650–9.
Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet (London, England). 2019;393:2051–8.
Gomez DR, Blumenschein GR Jr, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672–82.
Kim TH, Park S, Rim CH, et al. Improved oncologic outcomes by ablative radiotherapy in patients with bone metastasis from hepatocellular carcinoma. J Cancer Res Clin Oncol. 2021;147:2693–700.
Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10:181–223.
Jin K, Lan H, Wang X, et al. Genetic heterogeneity in hepatocellular carcinoma and paired bone metastasis revealed by next-generation sequencing. Int J Clin Exp Pathol. 2017;10:10495–504.
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet (London, England). 2018;391:1163–73.
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2017;389:56–66.
Zhu AX, Finn RS, Galle PR, et al. Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of α-fetoprotein. Lancet Oncol. 2019;20: e191.
Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54–63.
Funding
JSPS KAKENHI Grant, 20K08312, Noriyuki Akutsu.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Human/animal rights
All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Informed consent
Informed consent was obtained from the spouse of the patient for being included in the present report.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Akutsu, N., Kawakami, Y., Numata, Y. et al. A case of hepatocellular carcinoma with long-term survival by multidisciplinary treatment for cranial and skeletal muscle metastases. Clin J Gastroenterol 15, 960–967 (2022). https://doi.org/10.1007/s12328-022-01669-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-022-01669-7